Since 2021, G7 Finance and Health Ministers have reinforced their commitment to accelerating antimicrobial resistance (AMR) strategies, addressing the antibiotic pipeline and market failure, preserving access to essential antibiotics, and enhancing research and development (R&D) to bring new antibacterials to market, particularly for the vulnerable populations most impacted by AMR. The Global AMR R&D Hub and the World Health Organisation (WHO) presented a progress report to G7 Health and Finance Ministers in May 2022, with an update in 2023.
The current report provides an annual update on the financial landscape for antibacterial innovation, tracks country-by -country progress, and outlines key actions for the coming year to support G7 policy and activities.